LH
LABCORP HOLDINGS INC.
-0.25 (-0.08%)324.26USD175K成交股數26.3B市值26.8本益比(近四季)1.8股價營收比+5.8%營收年增(近四季)2026-10-27下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 3.7B+6% | 3.5B+6% | 3.5B+7% | 3.6B+11% | 3.5B+11% | 3.3B+10% | 3.3B+7% | 3.2B+6% | 3.2B | 3.0B | 3.1B | 3.0B |
| 營業成本 | 2.6B | 2.5B | 2.5B | 2.5B | 2.5B | 2.4B | 2.4B | 2.3B | 2.3B | 2.2B | 2.2B | 2.2B |
| 毛利 | 1.1B+6% | 1.0B+7% | 993M+10% | 1.0B+11% | 1.0B+17% | 948M+15% | 904M+6% | 926M+10% | 897M | 821M | 851M | 842M |
| 毛利率 | 29.8% | 28.7% | 28.2% | 28.8% | 29.7% | 28.3% | 27.6% | 28.8% | 28.2% | 27.1% | 27.8% | 27.8% |
| 研發費用 | – | – | – | – | – | – | – | – | – | – | – | – |
| 銷售管理費用 | 577M | 551M | 539M | 552M | 579M | 546M | 569M | 558M | 508M | 533M | 526M | 506M |
| 營業利益 | 452M+14% | 381M+17% | 268M+5% | 397M+35% | 395M+23% | 326M-365% | 254M+1% | 295M+11% | 321M | −123M | 252M | 266M |
| 營業利益率 | 12.1% | 10.8% | 7.6% | 11.1% | 11.2% | 9.7% | 7.7% | 9.2% | 10.1% | -4.0% | 8.3% | 8.8% |
| 稅後淨利 | 299M+26% | 278M+31% | 165M-2% | 261M+27% | 238M+4% | 213M-227% | 169M-8% | 205M+9% | 228M | −167M | 183M | 189M |
| 淨利率 | 8.0% | 7.9% | 4.7% | 7.3% | 6.7% | 6.4% | 5.2% | 6.4% | 7.2% | -5.5% | 6.0% | 6.2% |
| 稀釋 EPS | 3.64+28% | 3.35+33% | 1.98-1% | 3.12+28% | 2.84+6% | 2.52-236% | 2.00-5% | 2.43+15% | 2.69 | -1.85 | 2.11 | 2.12 |
| 稀釋股數 | 82.0M | 82.9M | 83.8M | 83.7M | 83.9M | 84.3M | 84.4M | 84.3M | 84.7M | 87.6M | 87.0M | 89.0M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 142M | 981M | 532M | 598M | 647M | 369M | 1.5B | 265M | 99.3M | 537M | 728M | 1.9B |
| 應收帳款 | 2.3B | 2.3B | 2.1B | 2.1B | 2.1B | 2.1B | 2.1B | 2.1B | 2.1B | 1.9B | 2.0B | 1.9B |
| 存貨 | 562M | 498M | 535M | 522M | 508M | 488M | 483M | 442M | 475M | 475M | 461M | 488M |
| 總資產 | 18.5B | 19.1B | 18.4B | 18.3B | 18.1B | 17.6B | 18.6B | 16.7B | 16.5B | 16.7B | 16.9B | 17.7B |
| 有息負債 | 5.9B | 5.8B | 5.1B | 5.1B | 5.1B | 5.6B | 5.4B | 3.0B | 3.0B | 4.1B | 4.4B | 5.0B |
| 總負債 | 9.9B | 10.3B | 9.8B | 9.5B | 9.6B | 9.3B | 10.4B | 8.7B | 8.6B | 8.8B | 9.0B | 8.9B |
| 股東權益 | 8.6B | 8.7B | 8.6B | 8.7B | 8.5B | 8.3B | 8.2B | 8.0B | 8.0B | 7.9B | 7.9B | 8.8B |
| 負債比 | 53.5% | 54.2% | 53.0% | 52.3% | 53.0% | 52.7% | 56.0% | 52.0% | 51.8% | 52.8% | 53.3% | 50.3% |
| 淨現金(現金 − 有息負債) | −5.7B | −4.9B | −4.6B | −4.5B | −4.4B | −5.2B | −3.8B | −2.8B | −2.9B | −3.5B | −3.7B | −3.1B |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 192M+935% | – | – | – | 18.5M | – | – | −29.8M | – | – | – |
| 資本支出 | – | 121M | – | – | – | 126M | – | – | 134M | – | – | – |
| 自由現金流 | – | 70.5M-166% | – | – | – | −108M | – | – | −164M | – | – | – |
| 折舊攤銷 | – | 173M | – | – | – | 167M | – | – | 155M | – | – | – |
| 買回庫藏股 | – | 98.0M | – | – | – | 0.00 | – | – | – | – | – | – |
| 現金股利 | – | 61.2M | – | – | – | 61.6M | – | – | 62.1M | – | – | – |
| 自由現金流率 | – | 2.0% | – | – | – | -3.2% | – | – | -5.2% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 14.0B
| Diagnostics | 10.9B | 77.8% | +7.2% |
|---|---|---|---|
| Biopharma Laboratory Services | 3.1B | 22.2% | +6.0% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 14.0B | +7.2% | 877M | 6.3% | 10.46 | 1.2B |
| FY2024 | 13.0B | +7.0% | 746M | 5.7% | 8.84 | 1.1B |
| FY2023 | 12.2B | +2.5% | 418M | 3.4% | 4.77 | 874M |
| FY2022 | 11.9B | -9.7% | 1.3B | 10.8% | 13.97 | 1.5B |
| FY2021 | 13.1B | -6.0% | 2.4B | 18.1% | 24.39 | 2.7B |
| FY2020 | 14.0B | +21.0% | 1.6B | 11.1% | 15.88 | 1.8B |
| FY2019 | 11.6B | +2.0% | 824M | 7.1% | 8.35 | 1.0B |
| FY2018 | 11.3B | – | 884M | 7.8% | 8.61 | 926M |